#South Korea #Seoul #Rznomics #RZ-001 #Hepatocellular Carcinoma

Rznomics Receives FDA RMAT Designation for RZ-001

In a promising development for the treatment of hepatocellular carcinoma (HCC), Rznomics, a pioneering biopharmaceutical firm specializing in RNA-based therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted its investigational candidate RZ-001 the Regenerative Medicine Advanced Therapy (RMAT) designation. This designation, which serves to expedite the development and review of groundbreaking therapies intended for serious or life-threatening conditions, recognizes the potential of RZ-001 based on compelling clinical data.

Background on RZ-001

RZ-001 represents a next-generation therapeutic developed from Rznomics' proprietary trans-splicing ribozyme platform, which allows for precise editing of RNA. By substituting cancer-specific RNA with therapeutic options, RZ-001 aims to provide a novel mechanism of action that addresses various limitations faced by traditional cancer therapies. With the dual benefits of enhancing tumor selectivity and improving safety, RZ-001 is particularly positioned as a promising alternative for patients with HCC who have limited treatment options.

Before receiving RMAT status, RZ-001 also earned Orphan Drug Designation (ODD) in 2024 and Fast Track Designation (FTD) in 2025 for HCC treatment, laying the groundwork for its recognition as a crucial therapeutic option in oncology.

Significance of RMAT Designation

The RMAT designation, established under the 21st Century Cures Act in 2016, is intended to encourage innovation by providing various incentives during the regulatory process. These include increased guidance from the FDA, eligibility for priority reviews, and access to accelerated approval pathways that are critical in terms of reducing the time it takes for promising therapies to reach the market. In particular, for conditions like HCC, which carry significant unmet medical needs, the RMAT designation is a substantial step toward facilitating faster patient access to impactful treatments.

Rznomics' vice president, Sung-woo Hong, expressed optimism about the designation, stating that it aligns with their goals to intensify development and establish partnerships within the U.S. market. The company intends to engage closely with the FDA in formal discussions about clinical trial design, Chemistry, Manufacturing, and Controls (CMC) plans, as well as commercialization strategies.

The Road Ahead for RZ-001

CEO Seong-Wook Lee highlighted the validation offered by the RMAT designation, asserting that it underscores the innovative qualities of their RNA editing platform. With priority now given to RZ-001's development, Rznomics aims to focus its resources on both global development and commercialization efforts, striving to provide a significant breakthrough in HCC therapeutics.

RZ-001 has shown promising preliminary response rates and safety profiles in the Phase 1b/2a clinical trials, with interim results presented at the American Association for Cancer Research (AACR) Annual Meeting. The recognition from the FDA reflects not only RZ-001’s potential but also the commitment of Rznomics to addressing critical healthcare challenges faced by patients worldwide.

About Rznomics

Based in South Korea, Rznomics is a clinical-stage biopharmaceutical company at the forefront of developing RNA-based gene therapies. The company’s unique ribozyme platform holds vast potential across multiple indications and has attracted significant industry attention. Following a successful collaboration with Eli Lilly in May 2025 to develop a new RNA editing therapeutic, Rznomics completed the listing of its shares on the KOSDAQ in December 2025 (KOSDAQ 476830).

For more details on Rznomics and its transformative therapies, you can visit their official website at www.rznomics.com.